This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen A et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 15: 1045–1056.
Jantunen E, Kuittinen T . Blood stem cell mobilization and collection in patients with lymphoproliferative disease: practical issues. Eur J Haematol 2008; 80: 287–295.
Bensinger W, DiPersio JF, McCarty JM . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 45: 181–195.
Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamäki E, Remes K . Low-dose or intermediate-dose cyclophosphamide plus granulocyte-colony stimulating factor for progenitor cell mobilization in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351.
Flomenberg N, Devine SM, DiPersio JF, Liesved JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.
Fruehauf S, Veldwijk MR, Seeger T, Schubert M, Laufs S, Topaly J et al A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009; 11: 992–1001.
Calandra G, McCarty J, McGuirk J, Tricot G, Crocker S-A, Badel K et al. AMD3100 plus G-CCF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef INM, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared to placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.
Dugan MJ, Maziarz RT, Bensinger W, Nademadee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma. Bone Marrow Transplant 2010; 45: 39–47.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr Jantunen has participated in EU leadership meetings organized by Genzyme.
Rights and permissions
About this article
Cite this article
Jantunen, E., Penttilä, K., Pyörälä, M. et al. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 46, 308–309 (2011). https://doi.org/10.1038/bmt.2010.93
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2010.93
This article is cited by
-
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma
Bone Marrow Transplantation (2020)
-
Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens
Bone Marrow Transplantation (2011)